Cantor Fitzgerald Issues Positive Forecast for VYGR Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Stock analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for shares of Voyager Therapeutics in a research note issued on Wednesday, March 12th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings per share of ($2.03) for the year, up from their previous forecast of ($2.20). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share.

VYGR has been the subject of several other research reports. Wells Fargo & Company set a $10.00 price objective on Voyager Therapeutics and gave the company an “overweight” rating in a report on Wednesday. Canaccord Genuity Group decreased their price objective on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday. Citigroup initiated coverage on Voyager Therapeutics in a report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price objective for the company. StockNews.com cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Wedbush reiterated an “outperform” rating on shares of Voyager Therapeutics in a report on Wednesday. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Voyager Therapeutics presently has an average rating of “Buy” and a consensus price target of $14.86.

Voyager Therapeutics Price Performance

Shares of NASDAQ VYGR opened at $3.90 on Friday. The stock has a market capitalization of $213.04 million, a price-to-earnings ratio of 5.49 and a beta of 0.99. The business has a 50-day moving average of $4.83 and a 200-day moving average of $5.82. Voyager Therapeutics has a fifty-two week low of $3.56 and a fifty-two week high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.24). Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $4.39 million during the quarter, compared to analyst estimates of $16.58 million. During the same period in the prior year, the business earned $1.25 EPS.

Institutional Investors Weigh In On Voyager Therapeutics

Hedge funds have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC acquired a new stake in shares of Voyager Therapeutics in the fourth quarter valued at approximately $29,000. Tower Research Capital LLC TRC raised its position in shares of Voyager Therapeutics by 133.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock valued at $31,000 after buying an additional 3,077 shares in the last quarter. Picton Mahoney Asset Management raised its position in shares of Voyager Therapeutics by 71.1% in the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after buying an additional 2,444 shares in the last quarter. Oxford Asset Management LLP acquired a new stake in shares of Voyager Therapeutics in the fourth quarter valued at approximately $60,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Voyager Therapeutics in the third quarter valued at approximately $74,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares in the company, valued at $634,653.20. This trade represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold 10,778 shares of company stock worth $58,548 over the last three months. Insiders own 4.53% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.